Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2)

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 3, 2008, Pages 973-978

  Methot, Joey L ^a   Chakravarty, Prasun K ^a   Chenard, Melissa ^a   Close, Joshua ^a   Cruz, Jonathan C ^a   Dahlberg, William K ^a   Fleming, Judith ^a   Hamblett, Christopher L ^a   Hamill, Julie E ^a   Harrington, Paul ^a   Harsch, Andreas ^a   Heidebrecht, Richard ^a   Hughes, Bethany ^a   Jung, Joon ^a   Kenific, Candia M ^a   Kral, Astrid M ^a   Meinke, Peter T ^a   Middleton, Richard E ^a   Ozerova, Nicole ^a   Sloman, David L ^a   Stanton, Matthew G ^a   Szewczak, Alexander A ^a   Tyagarajan, Sriram ^a   Witter, David J ^a   Paul Secrist, J ^a   Miller, Thomas A ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Biaryl; HDAC inhibitor; HDAC3; Internal cavity; Isoform selectivity

Indexed keywords

4 N ACETYLDINALINE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; HYDROXYBIPHENYL BENZAMIDE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PIPERAZYL BENZAMIDE; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; DRUG BINDING; HUMAN; HUMAN CELL; NONHUMAN; PHARMACOPHORE; RAT; STRUCTURE ACTIVITY RELATION;

BENZENE DERIVATIVES; BINDING SITES; HISTONE DEACETYLASES; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN ISOFORMS; REPRESSOR PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 38749136234     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.12.031     Document Type: Article

References (27)

1. Lund A.H., and van Lohuizen M. Genes Dev. 18 (2004) 2315
2. Bolden J.E., Peart M.J., and Johnstone R.W. Nat. Rev. Drug Discov. 5 (2006) 769
3. Blander G., and Guarente L. Annu. Rev. Biochem. 73 (2004) 417
4. Miller T.A., Witter D.J., and Belvedere S. J. Med. Chem. 46 (2003) 5097
5. Richon V.M. Br. J. Cancer 95 (2006) S2
6. O'Connor O.A.. Br. J. Cancer 95 (2006) S7
7. Duvic M., and Zhang C. Br. J. Cancer 95 (2006) S13
8. Marks P.A., and Breslow R. Nat. Biotechnol. 25 (2007) 84
9. Suzuki T., Ando T., Tsuchiya K., Fukazawa N., Saito A., Mariko Y., Yamashita T., and Nakanishi O. J. Med. Chem. 42 (1999) 3001
10. Kell J. Curr. Opin. Invest. Drugs 8 (2007) 485
11. Hamblett C.L., Methot J.L., Mampreian D.M., Sloman D.L., Stanton M.G., Kral A.M., Fleming J.C., Cruz J.C., Chenard M., Ozerova N., Hitz A.M., Wang H., Deshmukh S.V., Nazef N., Harsch A., Hughes B., Dahlberg W.K., Szewczak A.A., Middleton R.E., Mosley R.T., Secrist J.P., and Miller T.A. Bioorg. Med. Chem. Lett. 17 (2007) 5300
12. Knoepfler P.S., and Eisenman R.N. Cell 99 (1999) 447
13. Lagger G., O'Carroll D., Rembold M., Khier H., Tischler J., and Weitzer G. EMBO J. 21 (2002) 2672
14. Huang B.H., Laban M., Leung C.H., Lee L., Lee C.K., and Salto-Tellez M. Cell Death Differ. 12 (2005) 395
15. Wilson A.J., Byun D.-S., Popova N., Murray L.B., L'Italien K., Sowa Y., Arango D., Velcich A., Augenlicht L.H., and Mariadason J.M. J. Biol. Chem. 281 (2006) 13548
16. Grozinger C.M., Hassig C.A., and Schreiber S.L. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 4868
17. Fischle W., Dequiedt F., Fillion M., Hendzel M.J., Voelter W., and Verdin E. J. Biol. Chem. 276 (2001) 35826
18. Peart M.J., Smyth G.K., van Laar R.K., Bowtell D.D., Richon V.M., Marks P.A., Holloway A.J., and Johnstone R.W. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 3697
19. Karagiannis T.C., and El-Osta A. Leukemia 21 (2007) 61
20. Witter, D. J.; Harrington, P.; Wilson, K. J.; Fleming, J. C.; Kral, A. M.; Secrist, J. P.; Miller, T. A. submitted for publication. During the preparation of this manuscript, Methylgene, Inc., disclosed a similar observation:. Moradei O.M., Mallais T.C., Frechette S., Paquin I., Tessier P.E., Leit S.M., Fournel M., Bonfils C., Trachy-Bourget M.-C., Liu J., Yan T.P., Lu A.-H., Rahil J., Wang J., Lefebvre S., Li Z., Vaisburg A.F., and Besterman J.M. J. Med. Chem. 50 (2007) 5543
21. Benzamide 2 was originally designed for antiprotozoal (malaria) applications using total nuclear HDACs as a screening tool. Molecular modeling studies indicated that trichostatin A could overlay favorably with key elements of the apicidin pharmacophore: its ketone-containing side chain and indole moiety (similar analyses were performed using MS-275). Using modeling insights as guidance, rapid analog synthesis promptly yielded a series of potent hydroxamic acid derivatives. Incorporation of the o-hydroxy-benzamide moiety into this series as a metal chelating surrogate and further SAR development identified 2 which exhibited comparable intrinsic activity against total mammalian and protozoan nuclear HDACs. See:. Meinke P.T., and Liberator P.H. Curr. Med. Chem. 8 (2001) 211
22. For enzyme assay procedure, see Ref. 7.
23. For cell viability assay procedure, see Ref. 7.
24. Wang D.-F., Wiest O., Helquist P., Lan-Hargest H.-Y., and Wiech N.L. J. Med. Chem. 47 (2004) 3409
25. Vannini A., Volpari C., Gallinari P., Jones P., Mattu M., Carfi{dotless}́ A., De Francesco R., Steinkühler C., and Stefania Di Marco S. EMBO J. 8 (2007) 879
26. El-Beltagi H.M., Martens A.C.M., Lelieveld P., Haroun E.A., and Hagenbeek A. Cancer Res. 53 (1993) 3008
27. A solution of the inhibitor in 10% DMSO/45% PEG-400/45% water was administered once daily ip for up to 21 days.